A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Primo N LaraDavid R Gandara

Abstract

BMS-275291 is a selective matrix metalloproteinase inhibitor (MMPI) that does not inhibit sheddases implicated in the dose-limiting arthritis of older MMPIs. We conducted a randomized phase II trial of two doses of BMS-275291 (1,200 versus 2,400 mg) in hormone-refractory prostate cancer (HRPC) patients with bone metastases to probe for a dose-response relationship and to assess differential toxicities. Serial serum and urine specimens were collected to assess for markers of bone metabolism. The primary end point was 4-month progression-free survival (PFS). Eligibility criteria included documentation of androgen-independent disease (including anti-androgen withdrawal), skeletal metastasis, adequate end-organ function and performance status, and no more than one prior chemotherapy regimen. Patients were randomized to 1,200 mg orally once daily (arm A) or 1,200 mg orally twice daily (arm B). Response was assessed every 56 days. Eighty patients were enrolled: 39 in arm A and 41 in arm B. There were no responders by prostate-specific antigen or measurable disease to treatment. Stable disease was noted at 8 weeks in 39% of patients in arm A and in 17% of patients in arm B. Progression of disease at 8 weeks was seen in 61% of patients...Continue Reading

References

Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·D D ThompsonG A Rodan
Jun 1, 1981·Cancer·J J PollenJ D Schmidt
Oct 13, 1994·The New England Journal of Medicine·W J Catalona
Mar 1, 1996·Clinical & Experimental Metastasis·J G ConwayG M McGeehan
Jul 1, 1997·International Journal of Urology : Official Journal of the Japanese Urological Association·S Takeuchi, H Saitoh
Jun 5, 1999·Cancer Chemotherapy and Pharmacology·D E Kleiner, W G Stetler-Stevenson
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J BubleyG Wilding
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W KantoffN J Vogelzang
Jul 18, 2000·Cancer·A Fontana, P D Delmas
Jan 5, 2002·Journal of the National Cancer Institute·Jeffrey A NemethMichael L Cher
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S M AliA Lipton
Mar 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Naiyer A RizviHerbert Hurwitz
Mar 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kathy D MillerGeorge W Sledge
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Jan 6, 2005·Journal of the National Cancer Institute·Janet E BrownRobert E Coleman

❮ Previous
Next ❯

Citations

Mar 4, 2008·Journal of the National Cancer Institute·William M MerrittAnil K Sood
Jul 20, 2007·Arthritis Research & Therapy·Mandeep S Virk, Jay R Lieberman
Aug 1, 2013·Indian Journal of Pharmaceutical Sciences·R R Somani, U V Bhanushali
Oct 27, 2006·Expert Opinion on Emerging Drugs·Roy S Herbst
Jan 18, 2008·Journal of Pharmaceutical Sciences·Jose L Mauriz, Javier González-Gallego
Jun 15, 2011·Advanced Drug Delivery Reviews·Trenis D PalmerAndries Zijlstra
Jul 24, 2007·The Journal of Urology·Deborah A BradleyPhilip Kantoff
Dec 8, 2006·Surgical Oncology·Manit AryaHiten R Patel
Sep 8, 2007·BJU International·Bo AbrahamsenKim Brixen
May 3, 2006·Medicinal Research Reviews·Ana R QuesadaMiguel A Medina
Dec 3, 2010·The Journal of Pathology·Michael Allen, J Louise Jones
Dec 21, 2012·Expert Opinion on Therapeutic Targets·Ming-Hsien ChienShun-Fa Yang
Mar 31, 2009·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Yuval KonstantinoDavid A Fryburg
Jan 10, 2003·Seminars in Radiation Oncology·Dietmar W Siemann, Wenyin Shi
Apr 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Anna V ChristoforidouSergio Giralt
May 12, 2004·Urology·Oliver SartorUNKNOWN Quadramet 424Sm10/11 Study Group
Jun 29, 2013·Seminars in Oncology·Jean Hoffman-Censits, Maofu Fu
Feb 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H El-Maraghi, Elizabeth A Eisenhauer
Aug 8, 2008·Current Opinion in Supportive and Palliative Care·Amy M Lin, Eric J Small
Jun 22, 2013·The International Journal of Biological Markers·Wenzhao LiMasakazu Toi
May 8, 2018·Molecular Cancer Therapeutics·Arthur WinerPaolo Mignatti
Oct 18, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ulka N VaishampayanAnthony F Shields
Dec 7, 2020·European Journal of Medicinal Chemistry·Sandip Kumar BaidyaTarun Jha
Jul 27, 2021·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Anamarija HabičBarbara Breznik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.